Literature DB >> 31296921

Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA.

Kyung-Hee Kim1,2, Kawther Abu Elneel1, Jun Wan Shin1,2, Jae Whan Keum1, David Seong1, Seung Kwak3, Ramee Lee3, James F Gusella1,4,5, Marcy E MacDonald1,2,5, Ihn Sik Seong1,2, Jong-Min Lee6,7,8.   

Abstract

Huntington's disease (HD) is caused by an expanded CAG trinucleotide repeat in the first exon of the huntingtin gene (HTT). Since the entire course of the disease starts from this dominant gain-of-function mutation, lowering total or mutant huntingtin mRNA/protein has emerged as an appealing therapeutic strategy. We reasoned that endogenous mechanisms underlying HTT gene regulation may inform strategies to target the source of the disease. As part of our investigation to understand how the expression of HTT is controlled, we performed (1) complete sequencing analysis for mutant HTT 3'-UTR and (2) unbiased screening assays to identify naturally-occurring miRNAs that could lower the HTT mRNA levels. By sequencing HD families inheriting the major European mutant haplotype, we determined the full sequence of HTT 3'-UTRs of the most frequent mutant (i.e., hap.01) and normal (i.e., hap.08) haplotypes, revealing 5 sites with alternative alleles. In subsequent miRNA activity assays using the full-length hap.01 and hap.08 3'-UTR reporter vectors and follow-up validation experiments, hsa-miR-4324 and hsa-miR-4756-5p significantly reduced HTT 3'-UTR reporter activity and endogenous HTT protein levels. However, those miRNAs did not show strong haplotype-specific effects. Nevertheless, our data highlighting full sequences of HTT 3'-UTR haplotypes, effects of miRNAs on HTT levels, and potential interaction sites provide rationale and promising targets for total and mutant-specific HTT lowering intervention strategies using endogenous and artificial miRNAs, respectively.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31296921      PMCID: PMC7324902          DOI: 10.1038/s10038-019-0639-8

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  50 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

3.  MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.

Authors:  Jae-Jun Ban; Jin-Young Chung; Mijung Lee; Wooseok Im; Manho Kim
Journal:  Biochem Biophys Res Commun       Date:  2017-05-08       Impact factor: 3.575

4.  Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

Authors:  Dongbo Yu; Hannah Pendergraff; Jing Liu; Holly B Kordasiewicz; Don W Cleveland; Eric E Swayze; Walt F Lima; Stanley T Crooke; Thazha P Prakash; David R Corey
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects.

Authors:  Y P Goldberg; B Kremer; S E Andrew; J Theilmann; R K Graham; F Squitieri; H Telenius; S Adam; A Sajoo; E Starr
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

7.  A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing.

Authors:  Eulàlia Martí; Lorena Pantano; Mónica Bañez-Coronel; Franc Llorens; Elena Miñones-Moyano; Sílvia Porta; Lauro Sumoy; Isidre Ferrer; Xavier Estivill
Journal:  Nucleic Acids Res       Date:  2010-06-30       Impact factor: 16.971

8.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Authors:  Ryan L Boudreau; Jodi L McBride; Inês Martins; Shihao Shen; Yi Xing; Barrie J Carter; Beverly L Davidson
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

9.  microRNA-128a dysregulation in transgenic Huntington's disease monkeys.

Authors:  Jannet Kocerha; Yan Xu; Melinda S Prucha; Dongming Zhao; Anthony W S Chan
Journal:  Mol Brain       Date:  2014-06-13       Impact factor: 4.041

10.  MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.

Authors:  Eric R Reed; Jeanne C Latourelle; Jeremy H Bockholt; Joli Bregu; Justin Smock; Jane S Paulsen; Richard H Myers
Journal:  Neurology       Date:  2017-12-27       Impact factor: 11.800

View more
  3 in total

1.  Abnormal molecular signatures of inflammation, energy metabolism, and vesicle biology in human Huntington disease peripheral tissues.

Authors:  Andreas Neueder; Kerstin Kojer; Tanja Hering; Daniel J Lavery; Jian Chen; Nathalie Birth; Jaqueline Hallitsch; Sonja Trautmann; Jennifer Parker; Michael Flower; Huma Sethi; Salman Haider; Jong-Min Lee; Sarah J Tabrizi; Michael Orth
Journal:  Genome Biol       Date:  2022-09-07       Impact factor: 17.906

Review 2.  The emerging role of long non-coding RNAs, microRNAs, and an accelerated epigenetic age in Huntington's disease.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Kaveh Ebrahimzadeh; Rezvan Noroozi
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

3.  A genome-wide scan for candidate lethal variants in Thoroughbred horses.

Authors:  Evelyn T Todd; Peter C Thomson; Natasha A Hamilton; Rachel A Ang; Gabriella Lindgren; Åsa Viklund; Susanne Eriksson; Sofia Mikko; Eric Strand; Brandon D Velie
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.